Modality
ADC
MOA
PD-L1i
Target
SMN2
Pathway
Checkpoint
RSVETPompe
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Jun 2031
Phase 2Current
NCT05307402
2,592 pts·ET
2022-07→2031-06·Not yet recruiting
NCT03092959
66 pts·ET
2018-02→2030-03·Terminated
2,658 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-03-164.0y awayPh2 Data· ET
2031-06-245.2y awayPh2 Data· ET
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Termina…
P2
Not yet…
Catalysts
Ph2 Data
2030-03-16 · 4.0y away
ET
Ph2 Data
2031-06-24 · 5.2y away
ET
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05307402 | Phase 2 | ET | Not yet recr... | 2592 | UPDRS |
| NCT03092959 | Phase 2 | ET | Terminated | 66 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA |